Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Laekna, Inc. ( (HK:2105) ) just unveiled an update.
Laekna has granted a total of 15,323,500 restricted share units under its 2024 Share Award Scheme to employee participants and three executive directors, with no purchase price and a share closing price of HK$13.50 on the grant date. The awards vest in four equal annual tranches over four years, are subject to a clawback mechanism, and the grants to the three executive directors require approval from independent shareholders at the upcoming annual general meeting.
The remuneration committee considered past performance, current responsibilities, and expected future contributions in sizing the awards, and concluded that granting RSUs without performance targets is in line with market practice and company policy. The company emphasized compliance with Hong Kong listing limits on share-based incentives, clarified that most grantees are not insiders or major shareholders, and stated that no financial assistance will be provided to participants to acquire the RSUs, underscoring a focus on governance and alignment with shareholder interests.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a Cayman Islands–incorporated company listed on the Stock Exchange of Hong Kong. Operating in the biopharmaceutical sector, it focuses on developing innovative therapies and leverages equity-based incentives to attract and retain key talent in a competitive global life sciences market.
Average Trading Volume: 2,511,052
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.84B
See more insights into 2105 stock on TipRanks’ Stock Analysis page.